Reuters logo
BRIEF-Ariad says Brigatinib demonstrates 54 pct confirmed objective response rate in ALTA study
2016年6月6日 / 中午11点52分 / 1 年前

BRIEF-Ariad says Brigatinib demonstrates 54 pct confirmed objective response rate in ALTA study

June 6 (Reuters) - Ariad Pharma :

* Brigatinib demonstrates 54 percent confirmed objective response rate and 12.9-month median progression-free survival in ALTA study

* Of patients on 180 mg regimen with median follow-up of 8.3 months, 54 percent achieved confirmed objective response, trial’s primary endpoint Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below